☰

Katherine A. Hoadley, Ph.D. - Publications

Affiliations: 
2006 University of North Carolina, Chapel Hill, Chapel Hill, NC 
Area:
Bioinformatics, Genetics, Oncology
Tree Info Similar researchers PubMed Report error

182 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Zagami P, Fernandez-Martinez A, Rashid NU, Hoadley KA, Spears PA, Curigliano G, Perou CM, Carey LA. Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer. Jama Network Open. 6: e2348814. PMID 38117494 DOI: 10.1001/jamanetworkopen.2023.48814  0.568
2023 Xiang S, Zhang W, Liu S, Hoadley KA, Perou CM, Zhang K, Marron JS. PAIRWISE NONLINEAR DEPENDENCE ANALYSIS OF GENOMIC DATA. The Annals of Applied Statistics. 17: 2924-2943. PMID 38046186 DOI: 10.1214/23-aoas1745  0.471
2023 Sturgill IR, Raab JR, Hoadley KA. Expanded detection of alterations in cancer and tumor type-specific expression score comparison. Biorxiv : the Preprint Server For Biology. PMID 38045292 DOI: 10.1101/2023.11.21.568094  0.4
2023 Shi Y, Olsson LT, Hoadley KA, Calhoun BC, Marron JS, Geradts J, Niethammer M, Troester MA. Predicting early breast cancer recurrence from histopathological images in the Carolina Breast Cancer Study. Npj Breast Cancer. 9: 92. PMID 37952058 DOI: 10.1038/s41523-023-00597-0  0.399
2023 Rediti M, Fernandez-Martinez A, Venet D, Rothé F, Hoadley KA, Parker JS, Singh B, Campbell JD, Ballman KV, Hillman DW, Winer EP, El-Abed S, Piccart M, Di Cosimo S, Symmans WF, et al. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature Communications. 14: 7053. PMID 37923752 DOI: 10.1038/s41467-023-42635-2  0.7
2023 Tovey H, Sipos O, Parker JS, Hoadley KA, Quist J, Kernaghan S, Kilburn L, Salgado R, Loi S, Kennedy RD, Roxanis I, Gazinska P, Pinder SE, Bliss J, Perou CM, et al. Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF15. PMID 37574209 DOI: 10.1158/1078-0432.CCR-23-0370  0.658
2023 Hamilton AM, Van Alsten SC, Gao X, Nsonwu-Farley J, Calhoun BC, Love MI, Troester MA, Hoadley KA. Incorporating RNA-based Risk Scores for Genomic Instability to Predict Breast Cancer Recurrence and Immunogenicity in a Diverse Population. Cancer Research Communications. 3: 12-20. PMID 36968228 DOI: 10.1158/2767-9764.CRC-22-0267  0.457
2023 McClure MB, Kogure Y, Ansari-Pour N, Saito Y, Chao HH, Shepherd J, Tabata M, Olopade OI, Wedge DC, Hoadley KA, Perou CM, Kataoka K. Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals Aneuploidy-driven Metabolic Reprogramming. Cancer Research Communications. 3: 281-296. PMID 36860655 DOI: 10.1158/2767-9764.CRC-22-0073  0.739
2023 Walens A, Olsson LT, Gao X, Hamilton AM, Kirk EL, Cohen SM, Midkiff BR, Xia Y, Sherman ME, Nikolaishvili-Feinberg N, Serody JS, Hoadley KA, Troester MA, Calhoun BC. Protein-based immune profiles of basal-like vs. luminal breast cancers. Laboratory Investigation; a Journal of Technical Methods and Pathology. 101: 785-793. PMID 36775397 DOI: 10.1038/s41374-020-00506-0  0.349
2023 Fernandez-Martinez A, Pascual T, Singh B, Nuciforo P, Rashid NU, Ballman KV, Campbell JD, Hoadley KA, Spears PA, Pare L, Brasó-Maristany F, Chic N, Krop I, Partridge A, Cortés J, et al. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. Jama Oncology. PMID 36602784 DOI: 10.1001/jamaoncol.2022.6288  0.59
2022 Garcia-Recio S, Hinoue T, Wheeler GL, Kelly BJ, Garrido-Castro AC, Pascual T, De Cubas AA, Xia Y, Felsheim BM, McClure MB, Rajkovic A, Karaesmen E, Smith MA, Fan C, Ericsson PIG, ... ... Hoadley KA, et al. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nature Cancer. PMID 36585450 DOI: 10.1038/s43018-022-00491-x  0.715
2022 Damrauer JS, Beckabir W, Klomp J, Zhou M, Plimack ER, Galsky MD, Grivas P, Hahn NM, O'Donnell PH, Iyer G, Quinn DI, Vincent BG, Quale DZ, Wobker SE, Hoadley KA, et al. Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nature Communications. 13: 6658. PMID 36333289 DOI: 10.1038/s41467-022-33980-9  0.329
2022 Hamilton AM, Hoadley KA, Troester MA. Race and Ancestry in Immune Response to Breast Cancer. Cancer Discovery. 12: 2496-2497. PMID 36321309 DOI: 10.1158/2159-8290.CD-22-0852  0.427
2022 Walens A, Van Alsten SC, Olsson LT, Smith MA, Lockhart A, Gao X, Hamilton AM, Kirk EL, Love MI, Gupta GP, Perou CM, Vaziri C, Hoadley KA, Troester MA. RNA-based classification of homologous recombination deficiency in racially-diverse patients with breast cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 36129803 DOI: 10.1158/1055-9965.EPI-22-0590  0.527
2022 Samorodnitsky S, Hoadley KA, Lock EF. A hierarchical spike-and-slab model for pan-cancer survival using pan-omic data. Bmc Bioinformatics. 23: 235. PMID 35710340 DOI: 10.1186/s12859-022-04770-3  0.305
2022 Hurson AN, Abubakar M, Hamilton AM, Conway K, Hoadley KA, Love MI, Olshan AF, Perou CM, Garcia-Closas M, Troester MA. Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases. Npj Breast Cancer. 8: 74. PMID 35701440 DOI: 10.1038/s41523-022-00437-7  0.599
2022 Fassler DJ, Torre-Healy LA, Gupta R, Hamilton AM, Kobayashi S, Van Alsten SC, Zhang Y, Kurc T, Moffitt RA, Troester MA, Hoadley KA, Saltz J. Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression. Cancers. 14. PMID 35565277 DOI: 10.3390/cancers14092148  0.472
2022 Thennavan A, Beca F, Xia Y, Recio SG, Allison K, Collins LC, Tse GM, Chen YY, Schnitt SJ, Hoadley KA, Beck A, Perou CM. Molecular analysis of TCGA breast cancer histologic types. Cell Genomics. 1. PMID 35465400 DOI: 10.1016/j.xgen.2021.100067  0.608
2022 Hamilton AM, Hurson AN, Olsson LT, Walens A, Nsonwu-Farley J, Kirk EL, Abdou Y, Downs-Canner SM, Serody JS, Perou CM, Calhoun BC, Troester MA, Hoadley KA. The landscape of immune microenvironments in racially-diverse breast cancer patients. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 35437570 DOI: 10.1158/1055-9965.EPI-21-1312  0.553
2022 Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, et al. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2101506. PMID 35044810 DOI: 10.1200/JCO.21.01506  0.636
2022 Jones GS, Hoadley KA, Benefield H, Olsson LT, Hamilton AM, Bhattacharya A, Kirk EL, Tipaldos HJ, Fleming JM, Williams KP, Love MI, Nichols HB, Olshan AF, Troester MA. Racial differences in breast cancer outcomes by hepatocyte growth factor pathway expression. Breast Cancer Research and Treatment. PMID 35034243 DOI: 10.1007/s10549-021-06497-w  0.418
2021 Carmichael I, Calhoun BC, Hoadley KA, Troester MA, Geradts J, Couture HD, Olsson L, Perou CM, Niethammer M, Hannig J, Marron JS. JOINT AND INDIVIDUAL ANALYSIS OF BREAST CANCER HISTOLOGIC IMAGES AND GENOMIC COVARIATES. The Annals of Applied Statistics. 15: 1697-1722. PMID 35432688 DOI: 10.1214/20-aoas1433  0.56
2021 Hurson AN, Abubakar M, Hamilton AM, Conway K, Hoadley KA, Love MI, Olshan AF, Perou CM, Garcia-Closas M, Troester MA. TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 34737209 DOI: 10.1158/1055-9965.EPI-21-0661  0.563
2021 Little P, Jo H, Hoyle A, Mazul A, Zhao X, Salazar AH, Farquhar D, Sheth S, Masood M, Hayward MC, Parker JS, Hoadley KA, Zevallos J, Hayes DN. UNMASC: tumor-only variant calling with unmatched normal controls. Nar Cancer. 3: zcab040. PMID 34632388 DOI: 10.1093/narcan/zcab040  0.491
2021 Jones GS, Hoadley KA, Olsson LT, Hamilton AM, Bhattacharya A, Kirk EL, Tipaldos HJ, Fleming JM, Love MI, Nichols HB, Olshan AF, Troester MA. Hepatocyte growth factor pathway expression in breast cancer by race and subtype. Breast Cancer Research : Bcr. 23: 80. PMID 34344422 DOI: 10.1186/s13058-021-01460-5  0.388
2021 Robertson AG, Yau C, Carrot-Zhang J, Damrauer JS, Knijnenburg TA, Chambwe N, Hoadley KA, Kemal A, Zenklusen JC, Cherniack AD, Beroukhim R, Zhou W. Integrative modeling identifies genetic ancestry-associated molecular correlates in human cancer. Star Protocols. 2: 100483. PMID 33982016 DOI: 10.1016/j.xpro.2021.100483  0.328
2021 Walens A, Olsson LT, Gao X, Hamilton AM, Kirk EL, Cohen SM, Midkiff BR, Xia Y, Sherman ME, Nikolaishvili-Feinberg N, Serody JS, Hoadley KA, Troester MA, Calhoun BC. Protein-based immune profiles of basal-like vs. luminal breast cancers. Laboratory Investigation; a Journal of Technical Methods and Pathology. 101: 785-793. PMID 33623115 DOI: 10.1038/s41374-020-00506-0  0.349
2021 Benefield HC, Reeder-Hayes KE, Nichols HB, Calhoun BC, Love MI, Kirk EL, Geradts J, Hoadley KA, Cole SR, Earp HS, Olshan AF, Carey LA, Perou CM, Troester MA. Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features. Jnci Cancer Spectrum. 5: pkaa072. PMID 33442657 DOI: 10.1093/jncics/pkaa072  0.532
2020 Wheeler DA, Takebe N, Hinoue T, Hoadley KA, Cardenas MF, Hamilton AM, Laird PW, Wang L, Johnson A, Dewal N, Miller V, Piñeyro D, Castro de Moura M, Esteller M, Shen H, et al. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell. PMID 33217343 DOI: 10.1016/j.ccell.2020.10.015  0.347
2020 Fernandez-Martinez A, Krop IE, Hillman DW, Polley MY, Parker JS, Huebner L, Hoadley KA, Shepherd J, Tolaney S, Henry NL, Dang C, Harris L, Berry D, Hahn O, Hudis C, et al. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001276. PMID 33095682 DOI: 10.1200/JCO.20.01276  0.631
2020 Carrot-Zhang J, Chambwe N, Damrauer JS, Knijnenburg TA, Robertson AG, Yau C, Zhou W, Berger AC, Huang KL, Newberg JY, Mashl RJ, Romanel A, Sayaman RW, Demichelis F, Felau I, ... ... Hoadley KA, et al. Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer. Cancer Cell. 37: 639-654.e6. PMID 32396860 DOI: 10.1016/J.Ccell.2020.04.012  0.482
2020 Samorodnitsky S, Hoadley KA, Lock EF. A Pan-Cancer and Polygenic Bayesian Hierarchical Model for the Effect of Somatic Mutations on Survival. Cancer Informatics. 19: 1176935120907399. PMID 32116467 DOI: 10.1177/1176935120907399  0.436
2020 Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, et al. Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol. In press. European Urology. PMID 32037144 DOI: 10.1016/J.Eururo.2019.12.014  0.357
2020 Calabrese C, Davidson NR, Demircioğlu D, Fonseca NA, He Y, Kahles A, Lehmann KV, Liu F, Shiraishi Y, Soulette CM, Urban L, Greger L, Li S, Liu D, ... ... Hoadley KA, et al. Genomic basis for RNA alterations in cancer. Nature. 578: 129-136. PMID 32025019 DOI: 10.1038/S41586-020-1970-0  0.463
2020 Selitsky SR, Marron D, Hollern D, Mose LE, Hoadley KA, Jones C, Parker JS, Dittmer DP, Perou CM. Virus expression detection reveals RNA-sequencing contamination in TCGA. Bmc Genomics. 21: 79. PMID 31992194 DOI: 10.1186/S12864-020-6483-6  0.6
2020 Smith CC, Bixby LM, Miller KL, Selitsky SR, Bortone DS, Hoadley KA, Vincent BG, Serody JS. Using RNA Sequencing to Characterize the Tumor Microenvironment. Methods in Molecular Biology (Clifton, N.J.). 2055: 245-272. PMID 31502156 DOI: 10.1007/978-1-4939-9773-2_12  0.338
2020 Tovey H, Parker JS, Hoadley KA, Kennedy RD, Sipos O, Kilburn L, Kernaghan S, Gazinska P, Haider S, Pinder SE, Bliss J, Perou CM, Grigoriadis A, Tutt A, Cheang MCU. Evaluation of DNA repair biology signatures to predict specific carboplatin (C) versus docetaxel (D) benefit in advanced triple-negative breast cancer (aTNBC). Journal of Clinical Oncology. 38: 1074-1074. DOI: 10.1200/Jco.2020.38.15_Suppl.1074  0.655
2020 Earp HS, Olshan AF, Carey LA, Perou CM, Troester MA, Benefield HC, Reeder-Hayes KE, Nichols HB, Calhoun BC, Love MI, Sun X, Kirk EL, Geradts J, Hoadley KA, Cole SR. Abstract C045: Outcomes of hormone-receptor positive, HER2-negative breast cancers by race and tumor biologic features Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-C045  0.618
2020 Xia Y, Fan C, Hoadley KA, Parker JS, Perou CM. Abstract P4-05-12: Genetic determinants of the molecular portraits of epithelial cancers Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-05-12  0.735
2020 Hoadley KA, Powell BC, Kanavy D, Marron D, Mose LE, Hyslop T, Berry DA, Hahn O, Tolaney SM, Sikov WM, Perou CM, Carey LA. Abstract P4-05-03: Mutational analysis of triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-05-03  0.587
2020 King TA, Liu MC, McClure MB, Hinoue T, Kelly BJ, Creighton CJ, Bowen J, Leraas K, Burns RT, Coppens S, Rezk S, Garrett AL, Balko JM, Parker JS, Park BH, ... ... Hoadley KA, et al. Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs3-08  0.749
2020 Hamilton AM, Olsson LT, Calhoun BC, Hoadley KA, Troester MA. Abstract 1184: Association of immune microenvironment and race in the Carolina Breast Cancer Study Epidemiology. DOI: 10.1158/1538-7445.Am2020-1184  0.49
2019 Xia Y, Fan C, Hoadley KA, Parker JS, Perou CM. Genetic determinants of the molecular portraits of epithelial cancers. Nature Communications. 10: 5666. PMID 31827079 DOI: 10.1038/S41467-019-13588-2  0.728
2019 Zhang H, Schaefer A, Wang Y, Hodge RG, Blake DR, Diehl JN, Papageorge AG, Stachler MD, Liao J, Zhou J, Wu Z, Akarca FG, de Klerk LK, Derks S, Pierobon M, ... Hoadley KA, et al. Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. Cancer Discovery. PMID 31771969 DOI: 10.1158/2159-8290.Cd-19-0811  0.37
2019 Kamoun A, Reyniès A, Allory Y, Sjödahl G, Gordon Robertson A, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology. PMID 31563503 DOI: 10.1016/J.Eururo.2019.09.006  0.356
2019 Yu NY, Iftimi A, Yau C, Tobin NP, van 't Veer L, Hoadley KA, Benz CC, Nordenskjöld B, Fornander T, Stål O, Czene K, Esserman LJ, Lindström LS. Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer. Jama Oncology. PMID 31393518 DOI: 10.1001/Jamaoncol.2019.1856  0.458
2019 Gao GF, Parker JS, Reynolds SM, Silva TC, Wang LB, Zhou W, Akbani R, Bailey M, Balu S, Berman BP, Brooks D, Chen H, Cherniack AD, Demchok JA, Ding L, ... ... Hoadley KA, et al. Before and After: Comparison of Legacy and Harmonized TCGA Genomic Data Commons' Data. Cell Systems. 9: 24-34.e10. PMID 31344359 DOI: 10.1016/J.Cels.2019.06.006  0.533
2019 Picornell AC, Echavarria I, Alvarez E, López-Tarruella S, Jerez Y, Hoadley K, Parker JS, Del Monte-Millán M, Ramos-Medina R, Gayarre J, Ocaña I, Cebollero M, Massarrah T, Moreno F, García Saenz JA, et al. Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series. Bmc Genomics. 20: 452. PMID 31159741 DOI: 10.1186/S12864-019-5849-0  0.722
2019 Selitsky SR, Mose LE, Smith CC, Chai S, Hoadley KA, Dittmer DP, Moschos SJ, Parker JS, Vincent BG. Prognostic value of B cells in cutaneous melanoma. Genome Medicine. 11: 36. PMID 31138334 DOI: 10.1186/S13073-019-0647-5  0.536
2019 Waks AG, Stover DG, Guerriero JL, Dillon DA, Barry WT, Gjini E, Hartl CA, Lo WT, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, ... ... Hoadley KA, et al. The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31061067 DOI: 10.1158/1078-0432.Ccr-19-0173  0.636
2019 Arceci A, Bonacci T, Wang X, Stewart K, Damrauer JS, Hoadley KA, Emanuele MJ. FOXM1 Deubiquitination by USP21 Regulates Cell Cycle Progression and Paclitaxel Sensitivity in Basal-like Breast Cancer. Cell Reports. 26: 3076-3086.e6. PMID 30865895 DOI: 10.1016/J.Celrep.2019.02.054  0.493
2019 Williams LA, Hoadley KA, Nichols HB, Geradts J, Perou CM, Love MI, Olshan AF, Troester MA. Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas. Cancer Causes & Control : Ccc. PMID 30617775 DOI: 10.1007/S10552-018-1121-1  0.65
2019 Fernandez-Martinez A, Tanioka M, Fan C, Parker JS, Hoadley KA, Krop IE, Cortes J, Llombart Cussac A, Nuciforo P, Galván P, Pascual T, Partridge AH, Prat A, Carey LA, Perou CM. Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials. Journal of Clinical Oncology. 37: 571-571. DOI: 10.1200/Jco.2019.37.15_Suppl.571  0.679
2019 Kubler K, Karlic R, Haradhvala NJ, Ha K, Kim J, Kuzman M, Jiao W, Gakkhar S, Mouw KW, Braunstein LZ, Elemento O, Biankin AV, Rooman I, Miller M, Nogiec CD, ... ... Hoadley KA, et al. Abstract 2727: The premalignant state captured in the landscape of somatic mutations can reveal the cancer cell-of-origin Cancer Research. 79: 2727-2727. DOI: 10.1158/1538-7445.Am2019-2727  0.489
2019 Fernandez-Martinez A, Tanioka M, Fan C, Parker JS, Hoadley KA, Krop I, Partridge A, Carey L, Perou CM. Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer : A correlative analysis of the CALGB 40601 clinical trial (Alliance) Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz240  0.716
2018 Zhao X, Little P, Hoyle AP, Pegna GJ, Hayward MC, Ivanova A, Parker JS, Marron DL, Soloway MG, Jo H, Salazar AH, Papakonstantinou MP, Bouchard DM, Jefferys SR, Hoadley KA, et al. The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. Frontiers in Oncology. 8: 584. PMID 30662871 DOI: 10.3389/Fonc.2018.00584  0.572
2018 Kensler KH, Sankar VN, Wang J, Zhang X, Rubadue CA, Baker GM, Parker JS, Hoadley KA, Stancu AL, Pyle ME, Collins LC, Hunter DJ, Elissen AH, Hankinson SE, Tamimi RM, et al. PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study Cohorts. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 30591591 DOI: 10.1158/1055-9965.Epi-18-0863  0.579
2018 Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, Hoadley KA, Print C, Knowlton N, Black MA, Demaria S, Wang E, Bedognetti D, Jones WD, Mehta GA, et al. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. Oncoimmunology. 7: e1490854. PMID 30386679 DOI: 10.1080/2162402X.2018.1490854  0.65
2018 Corces MR, Granja JM, Shams S, Louie BH, Seoane JA, Zhou W, Silva TC, Groeneveld C, Wong CK, Cho SW, Satpathy AT, Mumbach MR, Hoadley KA, Robertson AG, Sheffield NC, et al. The chromatin accessibility landscape of primary human cancers. Science (New York, N.Y.). 362. PMID 30361341 DOI: 10.1126/Science.Aav1898  0.491
2018 Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman DI, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, et al. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discovery. PMID 30322867 DOI: 10.1158/2159-8290.Cd-18-0804  0.465
2018 Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, ... ... Hoadley KA, et al. Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Reports. 24: 1434-1444.e7. PMID 30089255 DOI: 10.1016/J.Celrep.2018.07.009  0.577
2018 Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, Hyslop TM, Pitcher BN, Soloway MG, Spears PA, Henry NL, Tolaney S, Dang CT, Krop I, Harris LN, et al. Integrated analysis of RNA and DNA from a phase III trial of trastuzumab-based neoadjuvant chemotherapy identifies response predictors in HER2-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30037817 DOI: 10.1158/1078-0432.Ccr-17-3431  0.692
2018 Williams LA, Butler EN, Sun X, Allott EH, Cohen SM, Fuller AM, Hoadley KA, Perou CM, Geradts J, Olshan AF, Troester MA. TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases. Npj Breast Cancer. 4: 13. PMID 29951581 DOI: 10.1038/s41523-018-0067-5  0.583
2018 Greytak SR, Engel KB, Zmuda E, Casas-Silva E, Guan P, Hoadley KA, Mungall AJ, Wheeler DA, Doddapaneni HV, Moore HM. National Cancer Institute Biospecimen Evidence-Based Practices: Harmonizing Procedures for Nucleic Acid Extraction from Formalin-Fixed, Paraffin-Embedded Tissue. Biopreservation and Biobanking. PMID 29920119 DOI: 10.1089/Bio.2018.0046  0.321
2018 Shen H, Shih J, Hollern DP, Wang L, Bowlby R, Tickoo SK, Thorsson V, Mungall AJ, Newton Y, Hegde AM, Armenia J, Sánchez-Vega F, Pluta J, Pyle LC, Mehra R, ... ... Hoadley KA, et al. Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Reports. 23: 3392-3406. PMID 29898407 DOI: 10.1016/J.Celrep.2018.05.039  0.325
2018 Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, ... ... Hoadley KA, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature Medicine. PMID 29713086 DOI: 10.1038/S41591-018-0009-7  0.651
2018 Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 173: 400-416.e11. PMID 29625055 DOI: 10.1016/J.Cell.2018.02.052  0.336
2018 Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortés-Ciriano I, Jayasinghe R, Chen F, Yu L, Sun S, ... ... Hoadley KA, et al. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell. 173: 305-320.e10. PMID 29625049 DOI: 10.1016/J.Cell.2018.03.033  0.38
2018 Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell. 173: 291-304.e6. PMID 29625048 DOI: 10.1016/J.Cell.2018.03.022  0.325
2018 Walter V, Yin X, Wilkerson MD, Cabanski CR, Zhao N, Du Y, Ang MK, Hayward MC, Salazar AH, Hoadley KA, Fritchie K, Sailey CJ, Weissler MC, Shockley WW, Zanation AM, et al. Correction: Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer Genes. Plos One. 13: e0194674. PMID 29543916 DOI: 10.1371/Annotation/E9Ad5950-A048-4A44-8E26-D8B07A9D4Bb8  0.376
2018 Siegel MB, He X, Hoadley KA, Hoyle A, Pearce JB, Garrett AL, Kumar S, Moylan VJ, Brady CM, Van Swearingen AE, Marron D, Gupta GP, Thorne LB, Kieran N, Livasy C, et al. Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. The Journal of Clinical Investigation. PMID 29480819 DOI: 10.1172/Jci96153  0.73
2018 Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, et al. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell. 33: 244-258.e10. PMID 29438696 DOI: 10.1016/J.Ccell.2018.01.003  0.423
2018 Echavarría I, López-Tarruella S, Picornell AC, Garcia-Saenz JA, Jerez-Gilarranz Y, Hoadley KA, Gomez H, Moreno F, Del Monte-Millán M, Marquez-Rodas I, Alvarez EL, Ramos-Medina R, Gayarre J, Massarrah T, Ocaña I, et al. Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29378733 DOI: 10.1158/1078-0432.Ccr-17-1912  0.629
2018 Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, et al. Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer. Journal of the National Cancer Institute. PMID 29361175 DOI: 10.1093/Jnci/Djx270  0.48
2018 Troester MA, Sun X, Allott EH, Geradts J, Cohen SM, Tse CK, Kirk EL, Thorne LB, Mathews M, Li Y, Hu Z, Robinson WR, Hoadley KA, Olopade OI, Reeder-Hayes KE, et al. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. Journal of the National Cancer Institute. 110. PMID 28859290 DOI: 10.1093/Jnci/Djx135  0.609
2018 Lei J, Shao J, Zhang J, Iglesia M, Chan D, Cao J, Anurag M, Singh P, Haricharan S, Kavuri S, Matsunuma R, Schmidt C, Kosaka Y, Crowder R, Hoog J, ... ... Hoadley K, et al. Abstract PD8-03: ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Pd8-03  0.539
2018 Liu J, Lichtenberg T, Hoadley K, Cherniack A, Poisson L, Kovatich A, Benz C, Thorsson V, Shriver C, Hu H. Abstract P3-16-01: Using the new pan-cancer clinical data resource (TCGA-CDR) to identify breast cancer genomic correlates associating with different survival outcome endpoints Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P3-16-01  0.459
2018 Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein J, Kamińska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwińska P, Mazurek S, Mishra L, Heyn H, ... ... Hoadley K, et al. Abstract LB-373: Comprehensive analysis of cancer stemness Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-373  0.455
2018 Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Hu H. Abstract 3287: An integrated TCGA pan-cancer clinical data resource to drive high quality survival outcome analytics Cancer Research. 78: 3287-3287. DOI: 10.1158/1538-7445.Am2018-3287  0.471
2017 Liu W, Snell JM, Jeck WR, Hoadley KA, Wilkerson MD, Parker JS, Patel N, Mlombe YB, Mulima G, Liomba NG, Wolf LL, Shores CG, Gopal S, Sharpless NE. Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis. Jci Insight. 2. PMID 29148985 DOI: 10.1172/jci.insight.98457  0.388
2017 Williams LA, Nichols HB, Hoadley KA, Tse CK, Geradts J, Bell ME, Perou CM, Love MI, Olshan AF, Troester MA. Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes & Control : Ccc. PMID 29124544 DOI: 10.1007/S10552-017-0977-9  0.598
2017 Esserman LJ, Yau C, Thompson CK, van 't Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjöld B, Fornander T, Stål O, Benz CC, Lindström LS. Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades. Jama Oncology. PMID 28662222 DOI: 10.1001/Jamaoncol.2017.1261  0.49
2017 Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports. 19: 2878-2880. PMID 28658632 DOI: 10.1016/J.Celrep.2017.06.008  0.316
2017 Bower JJ, Vance LD, Psioda M, Smith-Roe SL, Simpson DA, Ibrahim JG, Hoadley KA, Perou CM, Kaufmann WK. Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. Npj Breast Cancer. 3: 9. PMID 28649649 DOI: 10.1038/s41523-017-0009-7  0.628
2017 Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, Yoshimatsu TF, Pitt JJ, Hoadley KA, Troester M, Ru Y, Lichtenberg T, Sturtz LA, Shelley CS, Benz CC, et al. Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. Jama Oncology. PMID 28472234 DOI: 10.1001/Jamaoncol.2017.0595  0.64
2017 Seiler R, Ashab HA, Erho N, van Rhijn BW, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, ... ... Hoadley KA, et al. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. European Urology. PMID 28390739 DOI: 10.1016/J.Eururo.2017.03.030  0.417
2017 Sun X, Hoadley KA, Kim WY, Furberg H, Olshan AF, Troester MA. Age at diagnosis, obesity, smoking, and molecular subtypes in muscle-invasive bladder cancer. Cancer Causes & Control : Ccc. PMID 28321693 DOI: 10.1007/S10552-017-0885-Z  0.385
2017 Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, et al. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports. 18: 2780-2794. PMID 28297679 DOI: 10.1016/J.Celrep.2017.02.033  0.433
2017 Mehta GA, Parker JS, Silva GO, Hoadley KA, Perou CM, Gatza ML. Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. Breast Cancer Research and Treatment. PMID 28176176 DOI: 10.1007/S10549-017-4139-2  0.728
2017 Hoadley KA, Siegel MB, Kanchi KL, Miller CA, Ding L, Zhao W, He X, Parker JS, Wendl MC, Fulton RS, Demeter RT, Wilson RK, Carey LA, Perou CM, Mardis ER. Correction: Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. Plos Medicine. 14: e1002222. PMID 28068332 DOI: 10.1371/journal.pmed.1002222  0.683
2017 Seiler R, Winters B, Douglas J, van Rhijn BW, Sjödahl G, Lerner SP, Hoadley KA, North SA, McConkey DJ, Choi W, Kim WY, van Kessel KE, Thalmann GN, Davicioni E, Crabb SJ, et al. Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy. Journal of Clinical Oncology. 35: 281-281. DOI: 10.1200/Jco.2017.35.6_Suppl.281  0.452
2017 Lerner SP, Robertson G, Kim J, Cherniack A, Guo G, Akbani R, Kanchi RS, Hoadley KA, Hinoue T, Laird PW, Al-Ahmadie H, Bellmunt J, Castro M, Gordenin D, Mills GB, et al. Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas. Journal of Clinical Oncology. 35: 4500-4500. DOI: 10.1200/Jco.2017.35.15_Suppl.4500  0.42
2017 Tanioka M, Fan C, Carey L, Hyslop T, Pitcher B, Parker J, Hoadley K, Henry N, Tolaney S, Dang C, Krop I, Harris L, Berry D, Mardis E, Perou C, et al. Abstract S3-05: Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-S3-05  0.574
2017 Troester M, Sun X, Allott E, Kit C, Thorne L, Mathews M, Cohen S, Geradts J, Kirk E, Li Y, Hu Z, Robinson W, Hoadley K, Reeder-Hayes K, Earp S, et al. Abstract PD8-01: Race and age differences in PAM50 biomarker status in the Carolina breast cancer study Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Pd8-01  0.527
2017 Esserman L, Yau C, Thompson C, Veer Lv, Borowsky A, Hoadley K, Tobin N, Nordenskjöld B, Fornander T, Stål O, Benz C, Lindström L. Abstract PD7-02: Identification of breast cancers with an indolent disease course: 70 gene indolent threshold validation in a Swedish randomized trial of tamoxifen vs. not, with 20 year outcomes Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Pd7-02  0.542
2017 Lei J, Shao J, Zhang J, Iglesia M, Cao J, Chan D, He X, Kosaka Y, Schmidt C, Matsunuma R, Haricharan S, Crowder R, Hoog J, Phommaly C, Goncalves R, ... ... Hoadley K, et al. Abstract PD2-03: Recurrent functionally diverse in-frameESR1gene fusions drive endocrine resistance in breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Pd2-03  0.554
2017 Hoadley K, Hyslop T, Fan C, Berry D, Hahn O, Tolaney S, Sikov W, Perou C, Carey L. Abstract PD1-03: Multivariate analysis of subtype and gene expression signatures predictive of pathologic complete response (pCR) in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Pd1-03  0.516
2017 Huo D, Hu H, Rhie S, Gamazon E, Cherniack A, Liu J, Yoshimatsu T, Pitt J, Hoadley K, Troester M, Ru Y, Lichtenberg T, Sturtz L, Shelley C, Mills G, et al. Abstract P1-05-11: Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-05-11  0.542
2017 Amin S, Awadalla P, Biankin A, Boutros P, Brazma A, Brooks AN, Calabrese C, Chang D, Chateigner A, Chen K, Chong Z, Craft B, Creighton C, Demircioğlu D, Fonseca N, ... ... Hoadley K, et al. Abstract SY10-02: Pan-cancer study of recurrent and heterogeneous RNA aberrations and association with whole-genome variants Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Sy10-02  0.402
2017 Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Matsunuma R, He X, Singh P, Kosaka Y, Crowder R, Haricharan S, Kavuri S, Hoog J, Phommaly C, Goncalves R, ... ... Hoadley KA, et al. Abstract 1033: Estrogen receptor gene fusions drive endocrine therapy resistance in estrogen receptor positive breast cancer Cancer Research. 77: 1033-1033. DOI: 10.1158/1538-7445.Am2017-1033  0.611
2017 Picornell A, Echavarria Diaz-Guardamino I, Alvarez Castillo E, Lopez-Tarruella Cobo S, Jerez Y, Hoadley K, Parker J, del Monte-Millán M, Ramos Medina R, Gayarre J, Ocaña I, Cebollero M, Massarrah T, Moreno Antón F, García-Saenz J, et al. Breast cancer PAM50 subtypes: Correlation between RNA-Seq and multiplexed gene expression platforms Annals of Oncology. 28: v56-v57. DOI: 10.1093/Annonc/Mdx362.036  0.708
2017 Echavarria Diaz-Guardamino I, Picornell A, López-Tarruella S, Jerez Y, Hoadley K, Alvarez E, del Monte-Millán M, Gayarre J, Ramos-Medina R, Massarrah T, Ocaña I, Cebollero M, Moreno Antón F, García-Saenz J, Gomez Moreno H, et al. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification (TNBCtype-4) Annals of Oncology. 28: v48. DOI: 10.1093/Annonc/Mdx362.013  0.637
2017 Seiler R, Ashab H, Erho N, Van Rhijn B, Winters B, Douglas J, Van Kessel K, Fransen Van De Putte E, Sommerlad M, Wang Q, Choeurng V, Gibb E, Palmer-Aronsten B, Lam L, Buerki C, ... ... Hoadley K, et al. Muscle invasive bladder cancer: A single sample patient assay to predict molecular subtypes and benefit of neoadjuvant chemotherapy European Urology Supplements. 16: e1567-e1568. DOI: 10.1016/S1569-9056(17)30952-1  0.38
2017 Robertson AG, Gibb EA, Castro M, Carvalho BdS, Kim J, Al-Ahmadie H, Bellmunt J, Hoadley K, Weinstein JN, Kwiatkowski D, Lerner SP. Non-Coding RNA modulate molecular subtype biology in muscle invasive bladder cancer (MIBC) and are independently associated with survival Urologic Oncology: Seminars and Original Investigations. 35: 615. DOI: 10.1016/J.Urolonc.2017.06.026  0.358
2017 Seiler R, Ashab HAD, Erho N, Rhijn BWGv, Winters B, Douglas J, Kessel KV, Putte EEFvd, Sommerlad M, Wang Q, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, ... ... Hoadley KA, et al. Mp34-01 Molecular Subtypes Of Muscle Invasive Bladder Cancer Are Related To Benefit From Neoadjuvant Chemotherapy: Development Of A Single Sample Patient Assay The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1018  0.377
2016 Troester MA, Hoadley KA, D'Arcy M, Cherniack AD, Stewart C, Koboldt DC, Robertson AG, Mahurkar S, Shen H, Wilkerson MD, Sandhu R, Johnson NB, Allison KH, Beck AH, Yau C, et al. DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas. Npj Breast Cancer. 2: 16007. PMID 28721375 DOI: 10.1038/npjbcancer.2016.7  0.609
2016 Hoadley KA, Siegel MB, Kanchi KL, Miller CA, Ding L, Zhao W, He X, Parker JS, Wendl MC, Fulton RS, Demeter RT, Wilson RK, Carey LA, Perou CM, Mardis ER. Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. Plos Medicine. 13: e1002174. PMID 27923045 DOI: 10.1371/Journal.Pmed.1002174  0.691
2016 Heng YJ, Lester SC, Tse GM, Factor RE, Allison KH, Collins LC, Chen YY, Jensen KC, Johnson NB, Jeong JC, Punjabi R, Shin SJ, Singh K, Krings G, Eberhard DA, ... ... Hoadley KA, et al. The molecular basis of breast cancer pathological phenotypes. The Journal of Pathology. PMID 27861902 DOI: 10.1002/Path.4847  0.673
2016 Reaves DK, Hoadley KA, Fagan-Solis K, Jima DD, Bereman M, Thorpe L, Hicks J, McDonald D, Troester MA, Perou CM, Fleming JM. Nuclear localized LSR, a novel regulator of breast cancer behavior and tumorigenesis. Molecular Cancer Research : McR. PMID 27856957 DOI: 10.1158/1541-7786.Mcr-16-0085-T  0.626
2016 Li H, Zhu Y, Burnside ES, Huang E, Drukker K, Hoadley KA, Fan C, Conzen SD, Zuley M, Net JM, Sutton E, Whitman GJ, Morris E, Perou CM, Ji Y, et al. Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. Npj Breast Cancer. 2. PMID 27853751 DOI: 10.1038/npjbcancer.2016.12  0.587
2016 Liu W, Snell JM, Jeck WR, Hoadley KA, Wilkerson MD, Parker JS, Patel N, Mlombe YB, Mulima G, Liomba NG, Wolf LL, Shores CG, Gopal S, Sharpless NE. Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis. Jci Insight. 1: e88755. PMID 27734031 DOI: 10.1172/Jci.Insight.88755  0.566
2016 Lerner SP, McConkey DJ, Hoadley KA, Chan KS, Kim WY, Radvanyi F, Höglund M, Real FX. Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting. Bladder Cancer. 2: 37-47. PMID 27376123 DOI: 10.3233/BLC-150037  0.329
2016 Iglesia MD, Parker JS, Hoadley KA, Serody JS, Perou CM, Vincent BG. Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. Journal of the National Cancer Institute. 108. PMID 27335052 DOI: 10.1093/Jnci/Djw144  0.623
2016 Li H, Zhu Y, Burnside ES, Drukker K, Hoadley KA, Fan C, Conzen SD, Whitman GJ, Sutton EJ, Net JM, Ganott M, Huang E, Morris EA, Perou CM, Ji Y, et al. MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays. Radiology. 152110. PMID 27144536 DOI: 10.1148/Radiol.2016152110  0.633
2016 Zhao W, Hoadley KA, Parker JS, Perou CM. Identification of mRNA isoform switching in breast cancer. Bmc Genomics. 17: 181. PMID 26939613 DOI: 10.1186/S12864-016-2521-9  0.725
2016 Lerner SP, Kim J, Kwiatkowski DJ, Getz G, Weinstein JN, Cherniack A, Guo G, Akbani R, Hoadley KA, Kim WY, Robertson G, Mungall AJ, Hinoue T, Laird PW, Al-Ahmadie H, et al. Comprehensive characterization of 412 muscle invasive urothelial carcinomas: Final analysis of The Cancer Genome Atlas (TCGA) project. Journal of Clinical Oncology. 34: 405-405. DOI: 10.1200/Jco.2016.34.2_Suppl.405  0.445
2016 Thompson E, Asmann Y, Su X, Ellis M, Shao J, Hu Y, White K, Cherniack A, Hoadley K, Serie D, Perez E, Perou C. Abstract S4-02: A comprehensive analysis of fusion transcripts in breast cancer reveals associations between number of fusion transcripts, copy number events, gene expression profiles, and potentially clinical outcome Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-S4-02  0.494
2016 Siegel M, He X, Chen M, Hou J, Garrett A, Dye J, Silva G, Usary J, Moylan V, Brady C, Ma J, Thorne L, Hoadley K, Parker J, Anders C, et al. Abstract S4-01: Identification of early versus late drivers of breast tumors and metastasis Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-S4-01  0.548
2016 Heng YJJ, Jeong JC, Gendoo DMA, Haibe-Kains B, Ciriello G, Hoadley KA, Perou CM, Beck AH. Abstract 2627: Molecular analyses of histopathologic morphologic features in breast cancer Cancer Research. 76: 2627-2627. DOI: 10.1158/1538-7445.Am2016-2627  0.664
2016 Weinstein JN, Lerner SP, Kwiatkowski DJ, Getz G, Kim J, Al-ahmadie HA, Cherniack AD, Guo G, Akbani R, Hoadley KA, Kim WY, Robertson G, Mungall AJ, Hinoue T, Laird PW, et al. Abstract 128: Comprehensive molecular characterization of 412 muscle-invasive urothelial bladder carcinomas: final analysis of The Cancer Genome Atlas (TCGA) project Cancer Research. 76: 128-128. DOI: 10.1158/1538-7445.Am2016-128  0.514
2016 Robertson G, Gunaratne P, Lerner S, Mungall A, Brooks D, Bowlby R, Sipahimalani P, Jones S, Marra M, Hoadley K, Kwiatkowski D, Rosenberg J, Weinstein J. 787 The Cancer Genome Atlas (TCGA) project analysis of micro-RNA and gene expression subtypes of high-grade, muscle-invasive urothelial carcinoma European Urology Supplements. 15: e787. DOI: 10.1016/S1569-9056(16)60789-3  0.4
2015 Lerner SP, Weinstein J, Kwiatkowski D, Kim J, Robertson G, Hoadley KA, Akbani R, Creighton C. The Cancer Genome Atlas Project on Muscle-invasive Bladder Cancer. European Urology Focus. 1: 94-95. PMID 28723366 DOI: 10.1016/J.Euf.2014.11.002  0.414
2015 Wang P, Wu J, Ma S, Zhang L, Yao J, Hoadley KA, Wilkerson MD, Perou CM, Guan KL, Ye D, Xiong Y. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Reports. PMID 26686626 DOI: 10.1016/J.Celrep.2015.11.029  0.472
2015 Prat A, Fan C, Fernández A, Hoadley KA, Martinello R, Vidal M, Viladot M, Pineda E, Arance A, Muñoz M, Paré L, Cheang MC, Adamo B, Perou CM. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. Bmc Medicine. 13: 303. PMID 26684470 DOI: 10.1186/S12916-015-0540-Z  0.615
2015 Ruggles KV, Tang Z, Wang X, Grover H, Askenazi M, Teubl J, Cao S, McLellan MD, Clauser KR, Tabb DL, Mertins P, Slebos R, Erdmann-Gilmore P, Li S, Gunawardena HP, ... ... Hoadley KA, et al. An analysis of the sensitivity of proteogenomic mapping of somatic mutations and novel splicing events in cancer. Molecular & Cellular Proteomics : McP. PMID 26631509 DOI: 10.1074/Mcp.M115.056226  0.56
2015 Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, ... ... Hoadley KA, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. The New England Journal of Medicine. PMID 26536169 DOI: 10.1056/Nejmoa1505917  0.541
2015 Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, et al. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26527775 DOI: 10.1200/Jco.2015.62.1268  0.512
2015 Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, ... ... Hoadley KA, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 163: 506-19. PMID 26451490 DOI: 10.1016/J.Cell.2015.09.033  0.665
2015 Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, Smyla JK, Anderson JM, Kim HJ, Bentrem DJ, Talamonti MS, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nature Genetics. 47: 1168-78. PMID 26343385 DOI: 10.1038/Ng.3398  0.483
2015 Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, ... ... Hoadley K, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. The New England Journal of Medicine. 372: 2481-98. PMID 26061751 DOI: 10.1056/Nejmoa1402121  0.579
2015 Brown KE, Chagoya G, Kwatra SG, Yen T, Keir ST, Cooter M, Hoadley KA, Rasheed A, Lipp ES, Mclendon R, Ali-Osman F, Bigner DD, Sampson JH, Kwatra MM. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. Journal of Neurochemistry. 133: 730-8. PMID 25598002 DOI: 10.1111/Jnc.13032  0.408
2015 Sikov WM, Barry WT, Hoadley KA, Pitcher BN, Singh B, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Berry DA, Hahn OM, Carey LA, Perou CM, et al. Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S4-05  0.641
2015 Hoadley KA, Barry WT, Pitcher BN, Parker JS, Wilkerson MD, Irvin W, Henry NL, Tolaney SM, Dang C, Krop IE, Berry DA, Mardis ER, Perou CM, Winer EP, Hudis CA, et al. Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S3-06  0.712
2015 Ciriello G, Gatza ML, Hoadley KA, Zhang H, Rhie SK, Bowlby R, Wilkerson MD, Kandoth C, McLellan M, Cherniack A, Laird PW, Sander C, King TA, Perou CM. Abstract S2-04: Comprehensive molecular characterization of invasive lobular breast tumors Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S2-04  0.684
2015 Weinstein JN, Kim J, Creighton CJ, Akbani R, Hoadley KA, Kim WY, Morgan MB, Hinoue T, Cherniack A, Su X, Mungall AJ, Ryan MC, Bajorin DF, Rosenberg JE, Czerniak B, et al. Abstract 2969: Progress in The Cancer Genome Atlas bladder cancer project Cancer Research. 75: 2969-2969. DOI: 10.1158/1538-7445.Am2015-2969  0.377
2015 Keir ST, Rasheed BA, Hoadley KA, Roskoski MA, Gasinski D, Kwatra MM, Friedman HS, Bigner DD. Abstract 2435A: Identification and treatment data of xenografts representing TCGA-defined glioblastoma subtypes Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-2435A  0.454
2014 Sandhu R, Rein J, D'Arcy M, Herschkowitz JI, Hoadley KA, Troester MA. Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status. Carcinogenesis. 35: 2567-75. PMID 25123132 DOI: 10.1093/Carcin/Bgu175  0.707
2014 Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 158: 929-44. PMID 25109877 DOI: 10.1016/J.Cell.2014.06.049  0.6
2014 Prat A, Cruz C, Hoadley KA, Díez O, Perou CM, Balmaña J. Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. Breast Cancer Research and Treatment. 147: 185-91. PMID 25048467 DOI: 10.1007/S10549-014-3056-X  0.616
2014 Wilkerson MD, Cabanski CR, Sun W, Hoadley KA, Walter V, Mose LE, Troester MA, Hammerman PS, Parker JS, Perou CM, Hayes DN. Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Nucleic Acids Research. 42: e107. PMID 24970867 DOI: 10.1093/Nar/Gku489  0.647
2014 Iglesia MD, Vincent BG, Parker JS, Hoadley KA, Carey LA, Perou CM, Serody JS. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3818-29. PMID 24916698 DOI: 10.1158/1078-0432.Ccr-13-3368  0.719
2014 Zhao W, He X, Hoadley KA, Parker JS, Hayes DN, Perou CM. Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling. Bmc Genomics. 15: 419. PMID 24888378 DOI: 10.1186/1471-2164-15-419  0.585
2014 Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS, Kim WY. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proceedings of the National Academy of Sciences of the United States of America. 111: 3110-5. PMID 24520177 DOI: 10.1073/Pnas.1318376111  0.665
2014 Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RGW, McConkey D, Lerner S, Morgan M, Creighton CJ, Smith C, Cherniack AD, Kim J, Pedamallu CS, Noble MS, Al-Ahmadie HA, ... ... Hoadley KA, et al. Comprehensive molecular characterization of urothelial bladder carcinoma Nature. 507: 315-322. PMID 24476821 DOI: 10.1038/Nature12965  0.426
2014 Carey LA, Barry WT, Pitcher B, Hoadley KA, Cheang MCU, Anders CK, Henry NL, Tolaney SM, Dang CT, Krop IE, Harris L, Berry DA, Perou CM, Winer EP, Hudis CA. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). Journal of Clinical Oncology. 32: 506-506. DOI: 10.1200/Jco.2014.32.15_Suppl.506  0.658
2014 Weinstein JN, Kim J, Creighton CJ, Akbani R, Hoadley KA, Kim WY, Morgan MB, Hinoue T, Rosenberg JE, Bajorin DF, Hansel DE, Al-Ahmadie H, Gordenin D, Stuart JM, Robertson G, et al. Comprehensive molecular profiling of urothelial bladder cancer at the DNA, RNA, and protein levels: A TCGA project. Journal of Clinical Oncology. 32: 4509-4509. DOI: 10.1200/Jco.2014.32.15_Suppl.4509  0.477
2014 Weinstein JN, Kim J, Creighton CJ, Akbani R, Hoadley KA, Kim WY, Morgan MB, Hinoue T, Cherniack A, Su X, Mungall AJ, Ryan MC, Rosenberg JE, Bajorin DF, Czerniak B, et al. Abstract 987: Comprehensive characterization of urothelial bladder cancer: a TCGA Project update Cancer Research. 74: 987-987. DOI: 10.1158/1538-7445.Am2014-987  0.501
2014 Keir ST, Rasheed BA, Hoadley KA, Roskoski MA, Gasinski D, Killela PJ, Yan H, Kwatra MM, Friedman HS, Bigner DD. Abstract 838: Establishment, identification and treatment data of TCGA glioblatoma xenograft subtypes Cancer Research. 74: 838-838. DOI: 10.1158/1538-7445.Am2014-838  0.469
2014 Wolf DM, Fan C, Hoadley KA, Yau C, Sokolov A, Stuart J, Perou C, Veer Lv'. Abstract 360: Thousands of published cancer signatures and pathways can be collapsed into a handful of non-redundant gene programs: a TCGA pan-cancer analysis Cancer Research. 74: 360-360. DOI: 10.1158/1538-7445.Am2014-360  0.592
2013 Ciriello G, Sinha R, Hoadley KA, Jacobsen AS, Reva B, Perou CM, Sander C, Schultz N. The molecular diversity of Luminal A breast tumors. Breast Cancer Research and Treatment. 141: 409-20. PMID 24096568 DOI: 10.1007/S10549-013-2699-3  0.666
2013 Chen K, Navin NE, Wang Y, Schmidt HK, Wallis JW, Niu B, Fan X, Zhao H, McLellan MD, Hoadley KA, Mardis ER, Ley TJ, Perou CM, Wilson RK, Ding L. BreakTrans: uncovering the genomic architecture of gene fusions. Genome Biology. 14: R87. PMID 23972288 DOI: 10.1186/Gb-2013-14-8-R87  0.62
2013 Lock EF, Hoadley KA, Marron JS, Nobel AB. JOINT AND INDIVIDUAL VARIATION EXPLAINED (JIVE) FOR INTEGRATED ANALYSIS OF MULTIPLE DATA TYPES. The Annals of Applied Statistics. 7: 523-542. PMID 23745156 DOI: 10.1214/12-Aoas597  0.366
2013 Walter V, Yin X, Wilkerson MD, Cabanski CR, Zhao N, Du Y, Ang MK, Hayward MC, Salazar AH, Hoadley KA, Fritchie K, Sailey CJ, Sailey CG, Weissler MC, Shockley WW, et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. Plos One. 8: e56823. PMID 23451093 DOI: 10.1371/Journal.Pone.0056823  0.363
2013 Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, ... ... Hoadley KA, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. The Journal of Clinical Investigation. 123: 517-25. PMID 23257362 DOI: 10.1172/Jci65833  0.431
2013 Brauer HA, Makowski L, Hoadley KA, Casbas-Hernandez P, Lang LJ, Romàn-Pèrez E, D'Arcy M, Freemerman AJ, Perou CM, Troester MA. Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 571-85. PMID 23236214 DOI: 10.1158/1078-0432.Ccr-12-2123  0.614
2013 Walter V, Yin X, Wilkerson MD, Cabanski CR, Zhao N, Du Y, Ang MK, Hayward MC, Salazar AH, Hoadley KA, Fritchie K, Sailey CJ, Weissler MC, Shockley WW, Zanation AM, et al. Erratum: Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes (PLoS ONE (2013) 8:7 DOI:10.1371/annotation/b42f61c5-cb7e-49ca-8cd6-6e1f7903ad08) Plos One. 8. DOI: 10.1371/Annotation/B42F61C5-Cb7E-49Ca-8Cd6-6E1F7903Ad08  0.369
2013 Herschkowitz JI, Coarfa C, Prat A, Toneff MJ, Hoadley KA, Dinger ME, Mattick JS, Mani SA, Perou CM, Rosen JM. Abstract A039: The role of long noncoding RNAs in epithelial to mesenchymal transition and cancer stem cells Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A039  0.612
2013 Hoadley KA, Fan C, Wilkerson MD, Mose LE, Jefferys SR, Auman JT, Parker JS, Hayes DN, Perou CM. Abstract SY12-03: Multi-tumor analysis of TCGA data identifies expression commonalities across tumor types. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Sy12-03  0.679
2013 Gatza M, Silva G, Hoadley K, Fan C, Perou C. Abstract S4-01: An integrated genomics approach identifies novel drivers of oncogenic pathway activity in human breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-S4-01  0.672
2012 Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, ... ... Hoadley KA, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2615-23. PMID 22665533 DOI: 10.1200/Jco.2010.34.5579  0.591
2012 Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, ... Hoadley KA, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 149: 307-21. PMID 22500798 DOI: 10.1016/J.Cell.2012.02.053  0.556
2012 Brauer HA, Makowski L, Hoadley KA, Lang LJ, Freemerman AJ, Perou CM, Troester MA. Impact of stromal microenvironment on metabolic phenotypes in breast cancer: evidence for stroma-influenced Warburg effect Bmc Proceedings. 6. DOI: 10.1186/1753-6561-6-S3-P8  0.604
2012 Wilkerson MD, Sun W, Wang K, Cabanski CR, Hoadley KA, Liu J, Prins J, Hayes DN. Abstract 3975: Detecting patient mutomes by integrating DNA and RNA sequencing Cancer Research. 72: 3975-3975. DOI: 10.1158/1538-7445.Am2012-3975  0.379
2012 Hoadley K, Parker J, Wilkerson, Mose L, Jefferys S, Soloway M, Turman Y, Auman J, Hayes D, Perou C. Abstract S6-1: Exploration of isoform switching and mutation expression in breast cancer by mRNA-sequencing analysis Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-S6-1  0.65
2012 Koboldt DC, Fulton RS, McLellan MD, Schmidt H, Kalicki-Veizer J, McMichael JF, Fulton LL, Dooling DJ, Ding L, Mardis ER, Wilson RK, Ally A, Balasundaram M, Butterfield YSN, Carlsen R, ... ... Hoadley KA, et al. Comprehensive molecular portraits of human breast tumours Nature. 490: 61-70. DOI: 10.1038/Nature11412  0.743
2011 Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, Marcom PK, Carey LA, Potti A, Nevins JR, Perou CM. Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer Breast Cancer Research. 13. DOI: 10.1186/bcr2909  0.687
2010 Thorner AR, Parker JS, Hoadley KA, Perou CM. Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. Plos One. 5: e13073. PMID 20949095 DOI: 10.1371/Journal.Pone.0013073  0.796
2010 Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, Muldrew K, Miller CR, Randell SH, Socinski MA, Parsons AM, Funkhouser WK, Lee CB, Roberts PJ, Thorne L, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4864-75. PMID 20643781 DOI: 10.1158/1078-0432.Ccr-10-0199  0.517
2010 Nitta M, Kozono D, Kennedy R, Stommel J, Ng K, Zinn PO, Kushwaha D, Kesari S, Inda MM, Wykosky J, Furnari F, Hoadley KA, Chin L, DePinho RA, Cavenee WK, et al. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. Plos One. 5: e10767. PMID 20532243 DOI: 10.1371/Journal.Pone.0010767  0.346
2010 Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 17: 510-22. PMID 20399149 DOI: 10.1016/J.Ccr.2010.03.017  0.534
2010 Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17: 98-110. PMID 20129251 DOI: 10.1016/J.Ccr.2009.12.020  0.516
2009 Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, Marcom PK, Carey LA, Potti A, Nevins JR, Perou CM. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Research : Bcr. 11: R55. PMID 19638211 DOI: 10.1186/Bcr2344  0.752
2009 Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC, Perou CM. In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene. 28: 742-51. PMID 19043454 DOI: 10.1038/Onc.2008.430  0.799
2009 Carey L, O'Shaughnessy J, Hoadley K, Khambata-Ford S, Horak C, Xu L, Awad M, Brickman D, Muller S, Donato J, Asmar L, Stiljeman I, Ebbert M, Bernard P, Perou C. Potential Predictive Markers of Benefit from Cetuximab in Metastatic Breast Cancer: An Analysis of Two Randomized Phase 2 Trials. Cancer Research. 69: 2014-2014. DOI: 10.1158/0008-5472.Sabcs-09-2014  0.588
2009 Troester MA, Herschkowitz JI, Hoadley KA. Molecular signatures of drug resistance Drug Resistance in Cancer Cells. 271-294. DOI: 10.1007/978-0-387-89445-4_12  0.656
2007 Jiang J, Parker CE, Hoadley KA, Perou CM, Boysen G, Borchers CH. Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR diagnosis. Proteomics. Clinical Applications. 1: 1651-9. PMID 21136662 DOI: 10.1002/Prca.200700009  0.486
2007 Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA, Perou CM. EGFR associated expression profiles vary with breast tumor subtype. Bmc Genomics. 8: 258. PMID 17663798 DOI: 10.1186/1471-2164-8-258  0.631
2007 Penland SK, Keku TO, Torrice C, He X, Krishnamurthy J, Hoadley KA, Woosley JT, Thomas NE, Perou CM, Sandler RS, Sharpless NE. RNA expression analysis of formalin-fixed paraffin-embedded tumors. Laboratory Investigation; a Journal of Technical Methods and Pathology. 87: 383-91. PMID 17297435 DOI: 10.1038/Labinvest.3700529  0.542
2006 Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, Barbier CS, Perou CM. Gene expression patterns associated with p53 status in breast cancer. Bmc Cancer. 6: 276. PMID 17150101 DOI: 10.1186/1471-2407-6-276  0.825
2005 Hoadley K, Perou C. Identification of drug targets for the treatment of Basal-like tumors Breast Cancer Research. 7: 1-1. DOI: 10.1186/Bcr1191  0.606
2004 Troester MA, Hoadley KA, Parker JS, Perou CM. Prediction of toxicant-specific gene expression signatures after chemotherapeutic treatment of breast cell lines. Environmental Health Perspectives. 112: 1607-13. PMID 15598611 DOI: 10.1289/Txg.7204  0.636
2004 Troester MA, Hoadley KA, Sørlie T, Herbert BS, Børresen-Dale AL, Lønning PE, Shay JW, Kaufmann WK, Perou CM. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Research. 64: 4218-26. PMID 15205334 DOI: 10.1158/0008-5472.Can-04-0107  0.592
Show low-probability matches.